INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
INO$1.51+24.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $44,273,319 | $65,813,297 |
| Short-term investments | 14,239,145 | 28,300,232 |
| Prepaid expenses and other current assets, including from affiliated entity | 2,610,882 | 3,716,521 |
| Total current assets | 61,123,346 | 97,830,050 |
| Fixed assets, net | 2,527,603 | 3,659,818 |
| Investments in affiliated entity | 2,103,688 | 1,613,844 |
| Operating lease right-of-use assets | 6,542,923 | 8,113,840 |
| Other assets | 2,012,475 | 1,979,654 |
| Total assets | $74,310,035 | $113,197,206 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $11,053,618 | $16,200,013 |
| Accounts payable and accrued expenses due to affiliated entity | 74,473 | 1,351,163 |
| Accrued clinical trial expenses | 650,680 | 2,021,860 |
| Common stock warrant liabilities | 29,067,162 | 13,255,188 |
| Operating lease liability | 2,822,622 | 2,497,360 |
| Total current liabilities | 43,668,555 | 35,325,584 |
| Operating lease liability, net of current portion | 6,545,204 | 9,367,827 |
| Total liabilities | 50,213,759 | 44,693,411 |
| Commitments and contingencies | ||
| Inovio Pharmaceuticals, Inc. stockholders’ equity: | ||
| Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2025 and 2024 | — | — |
| Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2025 and 2024, issued and outstanding: 68,996,647 at December 31, 2025 and 36,099,991 at December 31, 2024 | 68,997 | 36,099 |
| Additional paid-in capital | 1,839,830,405 | 1,799,362,625 |
| Accumulated deficit | (1,815,165,163) | (1,730,219,262) |
| Accumulated other comprehensive loss | (637,963) | (675,667) |
| Total Inovio Pharmaceuticals, Inc. stockholders’ equity | 24,096,276 | 68,503,795 |
| Total liabilities and stockholders’ equity | $74,310,035 | $113,197,206 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.